



## **InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024**

**22 April, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that the company changes the date for when the interim report for Q1 2024 will be published. The interim report will now be published on Friday April 26, 2024 instead of Tuesday May 7, 2024 as previously communicated.**

The reason for bringing forward the publication of the interim report is to facilitate and speed up the process of determining if the reverse merger being evaluated is achievable.

### **For more information:**

Jenny Sundqvist, CEO

Phone: +46 8 122 038 50

E-mail: [jenny.sundqvist@indexpharma.com](mailto:jenny.sundqvist@indexpharma.com)

Johan Giléus, CFO and deputy CEO

Phone: +46 8 122 038 50

E-mail: [johan.gileus@indexpharma.com](mailto:johan.gileus@indexpharma.com)

### **Publication**

The information was submitted for publication through the agency of the contact person set out above at 09.15 CET on April 22, 2024.

*This is an English translation of the Swedish press release. In case of discrepancies between the English translation and the Swedish press release, the Swedish press release shall prevail. Information in this press release is intended for investors.*

### **InDex Pharmaceuticals in brief**

InDex Pharmaceuticals has a vision to help patients with immunological diseases where there is a high unmet medical need. Cobitolimod was being evaluated in the phase III program CONCLUDE for moderate to severe left-sided ulcerative colitis – a debilitating, chronic inflammation of the large intestine.

InDex Pharmaceuticals is based in Stockholm, Sweden. The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com).